title: Regulation of extragonadal insulin-like growth factor-binding protein-3 by testosterone in oophorectomized women.
abstract: Insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) is the principal carrier protein of IGF-I in the circulation. IGF-I has been postulated to play a role in the genesis and maintenance of the polycystic ovary syndrome. Regardless of the exact mechanism of action of IGF-I on ovarian steroidogenesis, alterations in the level of IGFBP-3 may play a significant role in regulating the concentration of IGF-I in hyperandrogenism. We have postulated that androgens reduce the circulating IGFBP-3 concentration through a mechanism similar to its suppression of the hepatic production of sex hormone-binding globulin (SHBG), thereby increasing bioavailable IGF-I and amplifying its impact on ovarian steroidogenesis. To test this hypothesis, we studied seven oophorectomized women (aged 39-51 yr; body mass, 20.9-35.8 kg/m2) during 3 weeks of testosterone (T) propionate administration (20 mg, three times weekly). All subjects were receiving 0.625 or 1.25 mg conjugated estrogens/day. Blood was sampled before (week 0), during (weeks 1-3), and after (week 4) T administration. Serum was assayed for total T, GH, and SHBG, and plasma was assessed for IGF-I, insulin (INS), and IGFBP-3. IGFBP-3 was measured by both RIA and Western ligand blotting; (expressed as a percentage of the control value). Circulating T increased from 1.51 +/- 1.06 to 30.8 +/- 13.8 mmol/L by week 2 (P < 0.001). During T administration, IGF-I increased (from 55 +/- 23 ng/mL at week 0 to 124 +/- 37 ng/mL at week 4; P < 0.05); INS did not change, with the exception of a higher fasting level 1 week after discontinuing therapy, and GH decreased (from 1.7 +/- 2.3 micrograms/L at week 0 to 0.4 +/- 0.4 microgram/L at week 4; P < 0.03), as did the circulating SHBG concentration (397 +/- 205 to 273 +/- 93 nmol/L by week 2; P < 0.01). IGFBP-3 levels determined by Western ligand blot were higher during the second and third weeks of T administration (265 +/- 28% and 218 +/- 43% of control values, respectively; P < 0.05) compared to that at week 0 (165 +/- 44% of control values). However, there was no difference in the circulating concentration of IGFBP-3, determined by RIA, at weeks 0, 1, 3, and 4 (3.59 +/- 0.35, 4.00 +/- 0.79, 3.48 +/- 0.56, and 3.65 +/- 0.52 microgram/mL, respectively).(ABSTRACT TRUNCATED AT 400 WORDS)
authors.affiliation: Department of Obstetrics and Gynecology, University of Alabama, Birmingham 35233.
authors.forename: R
authors.initials: R
authors.lastname: Azziz
authors.forename: C L
authors.initials: CL
authors.lastname: Deal
authors.forename: H D
authors.initials: HD
authors.lastname: Potter
authors.forename: S E
authors.initials: SE
authors.lastname: Gargosky
authors.forename: R G
authors.initials: RG
authors.lastname: Rosenfeld
mesh_terms: D000328:Adult; D015153:Blotting, Western; D002352:Carrier Proteins / Q000097:blood*; D005260:Female; D013006:Growth Hormone / Q000097:blood; D006801:Humans; D007328:Insulin / Q000097:blood; D018969:Insulin-Like Growth Factor Binding Proteins; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D008875:Middle Aged; D010052:Ovariectomy; D011863:Radioimmunoassay; D012738:Sex Hormone-Binding Globulin / Q000378:metabolism; D013739:Testosterone / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*
chemical_list: D002352:Carrier Proteins; D007328:Insulin; D018969:Insulin-Like Growth Factor Binding Proteins; D012738:Sex Hormone-Binding Globulin; D013739:Testosterone; D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone